Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101: a First-in-Class Epigenome Editing approach for the Treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2-CMD)

A breakthrough approach and supporting data using epigenome editing technology for the treatment of a type of muscular dystrophy, LAMA2-congenital muscular dystrophy , a genetic disorder, is...

Related Keywords

Tokyo ,Japan ,Haru Morita ,Tokyo Stock Exchange Growth ,Modalis Therapeutics Corporation Tokyo Stock Exchange , ,Modalis Therapeutics Corporation ,Tokyo Stock Exchange ,Congenital Muscular Dystrophy ,Waltham Massachusetts ,Markets ,